On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Researchers assessed the associations between patients’ understanding of their prognosis and their end-of-life care decisions.
Black patients were more likely than White patients to have distant metastases.
Researchers present data on use of palliative care in the last 30 days of life and the impact on costs among those who did and did not receive palliative care.
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
Patients living in states with lower eligibility limits had worse survival rates, regardless of cancer stage at diagnosis.